ALR Technologies Announces Successful Preliminary Results
for the GluCurve Pet CGM Non-Inferiority Study
( February 28, 2022 – Singapore) ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB:
ALRT), the diabetes management company, today announced preliminary results from the NonInferiority Study currently being conducted on the GluCurve Pet CGM (GluCurve).
Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with
the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements
set for human blood glucose meters in ISO: 15197:2013.
“We are pleased with GluCurve’s accuracy as compared to the leading pet BGM used by
veterinarians. The platform has provided valuable diagnostic information throughout the study
that would not be available from traditional in-clinic glucose curve. A significant benefit of
GluCurve is that it is applied in minutes in-clinic and the pet is sent home. GluCurve records
blood sugar levels every 3 minutes for up to 14 days while the pet and owner go about their
daily lives. This presents many benefits compared to BGM whereby 5 to 7 data points are
collected over 8-12 hours in a clinical setting. The process of housing a pet in-clinic and drawing
blood every 2 hours causes stress which elevates their blood glucose levels and is challenging
for the clinic staff to undertake. As part of the study, GluCurve was able to document the
impact on glucose levels from the stressful clinical experience required for BGM testing in real
time,” said Joe Stern, Head of Animal Health at ALR Technologies.
Mr. Stern continues, “The data collected by GluCurve is processed and organized to facilitate
clinicians in providing optimal care with ease. By comparing daily curves, the platform is able to
show clinicians if the pet is receiving insulin injections at the appropriate times, the pet’s eating
habits, and a complete view of the pet’s blood sugar levels over time. Additionally, we have
received feedback from the lead veterinarian in the study confirming what other veterinarians
and animal health companies have told us; they believe the GluCurve Pet CGM will become the
standard of care for the management of diabetic pets. We are looking forward to reviewing the
final results with our prospective pharmaceutical partner next month.
Sorry for the ugly format
